• Home
• Reports
• Companies

• Partnering Search
• Profiling
• Deal Negotiation

• Out-licensing
• In-licensing
• Services

• PL Intelligence
• Deals review
• Industry news

• Press releases
• Events
• Newsletter

Latest: Watch here for details of new products and services.

Pharmalicensing
is a division of
UTEK Europe Ltd

— RALEIGH, North Carolina, October 26

RALEIGH, North Carolina, October 26 /PRNewswire/ -- Most Successful Early Phase Trial - PRA International, a leading Clinical Research Organization, is pleased to announce that a study it has been conducting for one of its customers was awarded the "Most Successful Early Phase Trial" at the 2009 Good Clinical Practice Journal's (GCPj) Clinical Research Excellence Awards in London. The GCPj Awards recognize and reward corporate and individual excellence in clinical research, involving partnerships between sponsors, CROs and investigators. The study selected to win the award this year is one that PRA conducted as a Phase I study of a novel anti-thrombotic drug for Belgian biopharmaceutical company Ablynx.

"We are very proud to have collaborated with Ablynx on this study," commented Christa Raab, Director of Project Delivery for PRA. "Using biomarkers and PK/PD modeling for the study, the PRA project team, which included members from our Bioanalytical Laboratory in Assen, The Netherlands, worked closely with Ablynx."

About PRA International

PRA International conducts clinical trials in more than 65 countries across 6 continents and provides services through all phases of clinical development. PRA performs studies in all therapeutic areas, with specialization in Oncology, Neurosciences, Respiratory/Allergy, Cardiovascular and Infectious Diseases. PRA has supported over 2,100 clinical trials through its 36 global offices. PRA supports numerous trials across various phases with its bioanalytical lab in Assen, The Netherlands.

PRA's therapeutic expertise, global reach and project experience, combined with extensive local knowledge and our differentiating PERSONAL ELEMENT enable our project teams to deliver consistent and on time performance for our clients. This unique PRA philosophy - THE PERSONAL ELEMENT - recognizes that true client service comes only from trained, empowered and dedicated employees who are encouraged to use innovation and their personal commitment to accelerate the development lifecycle.

To learn more about PRA International, please visit www.PRAinternational.com, email Endpoints@PRAintl.com or call our Global Headquarters at +1-919-786-8200.

Get the Flash Player to see this rotator.

Press releases: Pharmalicensing current industry press releases.

Products:	Partnering Search	Company Profiling	Deal Negotiation	PL Intelligence	Reports	Comparision
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Services
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Press releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us